Our present investigation on the role of CAV-1 in radio-resistance, and important clinical findings based on cancer genome data suggest that CAV-1 gain of function mutation might be a driver mutation in lung cancer tumor aggression [41]. The gene discussed is CAV1; the disease is neoplasm.